News
Sarepta can begin shipping Elevidys therapy
Digest more
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Sarepta stock jumped after the drugmaker resumed shipments of the medicine Elevidys, previously paused by request by the FDA, following safety concerns.
Sarepta Therapeutics (NASDAQ:SRPT) shares dropped sharply premarket on Monday before paring losses as Barclays revised its ...
CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...
The European drug authority recommends refusal of marketing authorization after study shows no benefit over placebo.
The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could ...
Sarepta has suffered another regulatory setback after the European Medicines Agency’s (EMA’s) Committee for Medicinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback